Maribavir

Cytomegalovirus pUL97 Kinase Inhibitor — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Maribavir is an onp drug in the Cytomegalovirus pUL97 Kinase Inhibitor class catalogued in DrugCentral. It was first approved by the EMA in 2013. Its mechanism of action is classified as Breast Cancer Resistance Protein Inhibitors, Cytochrome P450 3A4 Inhibitors and Cytomegalovirus pUL97 Kinase Inhibitors. DrugCentral lists 2 molecular targets, including UL97 and HDAC6. Recorded indications include Post-transplant cytomegalovirus infection.

• Approval status: onp (first approved 2013 by the EMA).
• Drug class: Cytomegalovirus pUL97 Kinase Inhibitor.
• Mechanism of action: Breast Cancer Resistance Protein Inhibitors; Cytochrome P450 3A4 Inhibitors; Cytomegalovirus pUL97 Kinase Inhibitors.
• Molecular targets: UL97 and HDAC6 (2 listed in DrugCentral).
• Indications: Post-transplant cytomegalovirus infection.
• ATC code: J05AX10 (Other antivirals).
• Molecular formula: C15H19Cl2N3O4; molecular weight 376.23 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Post-transplant cytomegalovirus infection

Contraindications (2)

• Ganciclovir
• Valganciclovir

Mechanism & targets

• Mechanism of action (MoA): Breast Cancer Resistance Protein Inhibitors; Cytochrome P450 3A4 Inhibitors; Cytomegalovirus pUL97 Kinase Inhibitors; P-Glycoprotein Inhibitors
• Established pharmacologic class: Cytomegalovirus pUL97 Kinase Inhibitor

Molecular targets (2)

Target	Gene	Action	Activity
Serine/threonine protein kinase UL97	UL97	inhibitor	IC50 8.52
Histone deacetylase 6	HDAC6	unknown	IC50 6.17

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2021-11-23	FDA	—	TAKEDA PHARMS USA
2013-06-07	EMA	—	Takeda Pharmaceuticals International AG Ireland Branch	Yes

ATC classification

ATC code	Therapeutic hierarchy
J05AX10	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Other antivirals

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Drug resistance	438.3
Dysgeusia	422.6
Taste disorder	389.7
Viral load increased	255.5
Hospitalisation	235.2
Cytomegalovirus infection reactivation	218.4
Death	193.0
Cytomegalovirus viraemia	181.2
Cytomegalovirus infection	91.0
Cytomegalovirus test positive	77.0
Product use issue	72.5
Product distribution issue	53.4

Chemical structure

• Molecular formula: C₁₅H₁₉Cl₂N₃O₄
• Molecular weight: 376.23 g/mol
• CAS number: 176161-24-3
• InChIKey: KJFBVJALEQWJBS-XUXIUFHCSA-N
• PubChem CID: 471161

CC(C)NC1=NC2=CC(=C(C=C2N1[C@@H]3[C@H]([C@H]([C@@H](O3)CO)O)O)Cl)Cl

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Maribavir used for?

DrugCentral lists the following indications for Maribavir: Post-transplant cytomegalovirus infection.

How does Maribavir work?

Maribavir is classified as Breast Cancer Resistance Protein Inhibitors, Cytochrome P450 3A4 Inhibitors and Cytomegalovirus pUL97 Kinase Inhibitors; its molecular targets in DrugCentral include UL97 (inhibitor) and HDAC6.

When was Maribavir first approved?

Maribavir was first approved by the EMA in 2013.

What drug class does Maribavir belong to?

Maribavir is in the Cytomegalovirus pUL97 Kinase Inhibitor class.

What is the chemical formula of Maribavir?

Maribavir has the molecular formula C15H19Cl2N3O4 and a molecular weight of 376.23 g/mol.

Sources

• DrugCentral drug card 5496 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL515408 — compound record and bioactivity
• PubChem CID 471161 — chemical identifiers
• DrugBank DB06234 — drug record
• FDA UNII PTB4X93HE1 — substance identity
• DailyMed: FDA labels for Maribavir — current prescribing information (label search)
• UniProt Q9UBN7 (HDAC6) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.